• ObvioHealth

  Led · Series B · Jul 2021

  ObvioHealth operates the proprietary ObvioGo digital clinical trial platform, which provides automated study design and configuration, recruitment dashboards, site- and patient-facing tools for eConsent, eCOA, ePRO and EMR data integration. The company released ObvioGo 2.0 to streamline and automate clinical workflows for trial sites. ObvioGo is integrated with Oracle's EDC and CTMS software and provides automated data management, formatting and reporting capabilities. ObvioHealth intends to accelerate deployment of oncology clinical trials through a new strategic partnership and to expand research beyond the 35 countries where it already conducts trials. The alliance strengthens the company's domain expertise in oncology, a therapeutic area that represents more than 40 percent of all global clinical trials. Financially, the company announced a Series B extension totaling USD $18.4 million, capped by a strategic investment from Guardant Health. ObvioHealth is a healthtech company described in the article as a clinical-trials provider. The company operates in both the United States and Singapore. Filings with Singapore’s Accounting and Corporate Regulatory Authority (ACRA) report that ObvioHealth raised $15 million in its latest funding round. The article does not specify the financing instrument, investor names, valuation, or any participation breakdown. No operating metrics (revenue, user counts) or future plans were disclosed in the filings cited by the article. All information in this description is drawn from the ACRA filings referenced in the article. ObvioHealth operates a proprietary ecosystem and a downloadable decentralized clinical trial (DCT) app that lets participants take part in trials from home. In the four years since launch the company has been awarded nearly 40 studies from 28 blue-chip clients, implemented in 28 countries, across 16 therapeutic areas. Its platform includes GDPR-compliant bridging software to query EHR data and other tools for conducting virtual and hybrid trials. The company plans to boost IT capabilities, make key hires in Asia, and expand its Singapore office into a technology hub. Strategic partnerships with Dedalus and Novotech will integrate clinical research with EHR data for trial design and recruitment and establish ObvioHealth as Novotech's preferred provider for virtual trials in APAC. The business says the financing will support global growth, platform development, and expanded virtual-trial competencies. ObvioHealth offers a proprietary platform designed for digital and remote/at-home research that enables subjects to participate in studies from their homes. The platform integrates devices for real-time data collection and includes virtual chat features to boost protocol compliance. ObvioHealth positions its product as improving the experience for both research subjects and study sponsors. The company is led by Ivan Jarry and is based in Orlando, Florida. Recently it announced sponsorship of a virtual COVID-19 research study to monitor prevalence, symptoms and immune response of 10,000 U.S. participants over 12 months. The firm raised funding to support continued expansion of operations and its business reach. ObvioHealth Inc is described in the article as a contract research organisation (CRO). The company announced a $3 million Series A financing. The Series A was led by TKS I. TKS I is a Singapore-based venture fund focused on life sciences and healthcare. No additional operating metrics, past rounds, or future plans were disclosed in the article.

No current team members are available.